The discovery of NMO-IgG and AQP4 as its targeted antigen unequivocally confirmed neuromyelitis optica as a disease distinct from MS and allowed its early laboratorial recognition [31,32]. This evidence concerns the gene AQP4 and neuromyelitis optica.